Status:
COMPLETED
A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review
Lead Sponsor:
AbbVie
Conditions:
Atopic Dermatitis (AD)
Eligibility:
All Genders
12+ years
Brief Summary
Atopic Dermatitis (AD) is a common, chronic, and flaring systemic inflammatory skin disorder characterized by intensely pruritic and distressing skin eruptions. This study will assess treatment patter...
Eligibility Criteria
Inclusion
- Participants with at least one primary diagnosis of atopic dermatitis with ICD-10 code of L20.900 \[atopic dermatitis, unspecified\] or physician-confirmed atopic dermatitis documentation within the study period
- Participants with at least one documented health record of upadacitinib prescription that has a primary diagnosis of atopic dermatitis within the study period
- Participants with at least one atopic dermatitis severity measures (i.e., EASI) in the follow-up period including up to 6 months after the index date
Exclusion
- • Participants who did not fulfill the inclusion criteria will be excluded
Key Trial Info
Start Date :
August 6 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06503536
Start Date
August 6 2024
End Date
October 31 2024
Last Update
November 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital affiliated to Fudan University /ID# 268259
Shanghai, Shanghai Municipality, China, 200040